ES2600386B8 - Método de diagnóstico in vitro de la enfermedad de alzheimer basado en el nivel redox de la albúmina en el líquido cefalorraquídeo - Google Patents

Método de diagnóstico in vitro de la enfermedad de alzheimer basado en el nivel redox de la albúmina en el líquido cefalorraquídeo Download PDF

Info

Publication number
ES2600386B8
ES2600386B8 ES201631468A ES201631468A ES2600386B8 ES 2600386 B8 ES2600386 B8 ES 2600386B8 ES 201631468 A ES201631468 A ES 201631468A ES 201631468 A ES201631468 A ES 201631468A ES 2600386 B8 ES2600386 B8 ES 2600386B8
Authority
ES
Spain
Prior art keywords
alzheimer
diagnostic method
vitro diagnostic
albumin
cephalorrachid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201631468A
Other languages
English (en)
Other versions
ES2600386A1 (es
ES2600386B1 (es
Inventor
Ana Maria Ortiz Fernandez
Montserrat Costa Rierola
Salvador Grancha Gamon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols Worldwide Operations Ltd
Original Assignee
Grifols Worldwide Operations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES201631468A priority Critical patent/ES2600386B8/es
Application filed by Grifols Worldwide Operations Ltd filed Critical Grifols Worldwide Operations Ltd
Publication of ES2600386A1 publication Critical patent/ES2600386A1/es
Application granted granted Critical
Publication of ES2600386B1 publication Critical patent/ES2600386B1/es
Publication of ES2600386B8 publication Critical patent/ES2600386B8/es
Priority to AU2017251853A priority patent/AU2017251853B2/en
Priority to BR102017023388A priority patent/BR102017023388A2/pt
Priority to RU2017137768A priority patent/RU2696485C2/ru
Priority to MYPI2017001612A priority patent/MY179665A/en
Priority to NZ736919A priority patent/NZ736919B/en
Priority to KR1020170146307A priority patent/KR102189586B1/ko
Priority to CA2984732A priority patent/CA2984732C/en
Priority to PL17200206T priority patent/PL3324188T3/pl
Priority to US15/804,689 priority patent/US20180136236A1/en
Priority to TW106138311A priority patent/TWI699536B/zh
Priority to PT17200206T priority patent/PT3324188T/pt
Priority to TR2019/01544T priority patent/TR201901544T4/tr
Priority to ZA201707484A priority patent/ZA201707484B/en
Priority to CL2017002798A priority patent/CL2017002798A1/es
Priority to SG10201709117RA priority patent/SG10201709117RA/en
Priority to JP2017214113A priority patent/JP6639457B2/ja
Priority to EP17200206.5A priority patent/EP3324188B1/en
Priority to MX2017014218A priority patent/MX2017014218A/es
Priority to UY0001037469A priority patent/UY37469A/es
Priority to ES17200206T priority patent/ES2706539T3/es
Priority to CN201711080462.9A priority patent/CN108072762B/zh
Priority to IL255474A priority patent/IL255474B/en
Priority to ARP170103153A priority patent/AR110065A1/es
Priority to HK18109862.6A priority patent/HK1250395B/zh
Priority to US16/737,632 priority patent/US20200141951A1/en
Priority to US17/809,524 priority patent/US20220326259A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/74—Optical detectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6827—Total protein determination, e.g. albumin in urine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
    • G01N2333/765—Serum albumin, e.g. HSA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Método de diagnóstico in vitro de la enfermedad de Alzheimer basado en el nivel redox de la albúmina en el líquido cefalorraquídeo.#La presente invención se refiere a un método de diagnóstico in vitro de la enfermedad de Alzheimer (EA), que comprende las etapas de: a) determinar en una muestra de líquido cefalorraquídeo (LCR) el contenido de mercaptoalbúmina (HMA); y b) comparar el contenido determinado con el contenido de HMA en LCR de sujetos sanos. Si el contenido de HMA es menor que el de los sujetos sanos es indicativo de la EA.
ES201631468A 2016-11-16 2016-11-16 Método de diagnóstico in vitro de la enfermedad de alzheimer basado en el nivel redox de la albúmina en el líquido cefalorraquídeo Expired - Fee Related ES2600386B8 (es)

Priority Applications (27)

Application Number Priority Date Filing Date Title
ES201631468A ES2600386B8 (es) 2016-11-16 2016-11-16 Método de diagnóstico in vitro de la enfermedad de alzheimer basado en el nivel redox de la albúmina en el líquido cefalorraquídeo
AU2017251853A AU2017251853B2 (en) 2016-11-16 2017-10-27 In vitro diagnostic method for Alzheimer's disease based on the albumin redox level in the cerebrospinal fluid
BR102017023388A BR102017023388A2 (pt) 2016-11-16 2017-10-30 método de diagnóstico in vitro do mal de alzheimer baseado no nível redox da albumina no líquido cefalorraquidiano
RU2017137768A RU2696485C2 (ru) 2016-11-16 2017-10-30 Способ диагностирования in vitro болезни Альцгеймера на основании редокс-статуса альбумина в спинномозговой жидкости
MYPI2017001612A MY179665A (en) 2016-11-16 2017-11-01 In vitro diagnostic method for alzhemer's disease based on the albumin redox level in the cerebrospinal fluid
NZ736919A NZ736919B (en) 2016-11-16 2017-11-02 In vitro diagnostic method for alzheimer's disease based on the albumin redox level in the cerebrospinal fluid
CA2984732A CA2984732C (en) 2016-11-16 2017-11-03 In vitro diagnostic method for alzheimer's disease, based on the albumin redox level in the cerebrospinal fluid
KR1020170146307A KR102189586B1 (ko) 2016-11-16 2017-11-03 뇌 척수액 중 알부민 산화환원 수치에 기초된 알츠하이머 질환의 시험관 내 진단방법
ES17200206T ES2706539T3 (es) 2016-11-16 2017-11-06 Método de diagnóstico in vitro de la Enfermedad de Alzheimer basado en el nivel redox de la albúmina en el líquido cefalorraquídeo
CN201711080462.9A CN108072762B (zh) 2016-11-16 2017-11-06 基于脑脊液中白蛋白氧化还原水平的阿尔茨海默病的体外诊断方法
IL255474A IL255474B (en) 2016-11-16 2017-11-06 A method for the in vitro diagnosis of Alzheimer's disease based on the degree of oxidation of albumin in the cerebrospinal fluid
PT17200206T PT3324188T (pt) 2016-11-16 2017-11-06 Método de diagnóstico in vitro para a doença de alzheimer baseado no nível de redox de albumina no fluido cerebrospinal
UY0001037469A UY37469A (es) 2016-11-16 2017-11-06 Método de diagnóstico in vitro de la enfermedad de alzheimer basado en el nivel redox de la albúmina en el líquido cefalorraquídeo
TW106138311A TWI699536B (zh) 2016-11-16 2017-11-06 基於腦脊髓液中白蛋白氧化還原電位的阿茲海默氏症的體外診斷方法
PL17200206T PL3324188T3 (pl) 2016-11-16 2017-11-06 Sposób diagnostyczny in vitro dla choroby Alzheimera, oparty na poziomie albuminy redoks w płynie mózgowo-rdzeniowym
TR2019/01544T TR201901544T4 (tr) 2016-11-16 2017-11-06 Serebrospi̇nal sividaki̇ albümi̇n redoks sevi̇yesi̇ baz alinarak alzheimer hastaliğina yöneli̇k i̇n vi̇tro tani yöntemi̇
ZA201707484A ZA201707484B (en) 2016-11-16 2017-11-06 In vitro diagnostic method for alzheimer's disease based on the albumin redox level in the cerebrospinal fluid
CL2017002798A CL2017002798A1 (es) 2016-11-16 2017-11-06 Método de diagnóstico in vitro de la enfermedad de alzheimer basado en el nivel redox de la albúmina en el líquido cefalorraquídeo
SG10201709117RA SG10201709117RA (en) 2016-11-16 2017-11-06 In Vitro Diagnostic Method For Alzheimer's Disease Based On The Albumin Redox Level In The Cerebrospinal Fluid
JP2017214113A JP6639457B2 (ja) 2016-11-16 2017-11-06 脳脊髄液中のアルブミン酸化還元レベルに基づくアルツハイマー病のインビトロ診断方法
EP17200206.5A EP3324188B1 (en) 2016-11-16 2017-11-06 In vitro diagnostic method for alzheimer's disease based on the albumin redox level in the cerebrospinal fluid
MX2017014218A MX2017014218A (es) 2016-11-16 2017-11-06 Metodo de diagnostico in vitro de la enfermedad de alzheimer basado en el nivel redox de la albumina en el liquido cefalorraquideo.
US15/804,689 US20180136236A1 (en) 2016-11-16 2017-11-06 In vitro diagnostic method for alzheimer's disease based on the albumin redox level in the cerebrospinal fluid
ARP170103153A AR110065A1 (es) 2016-11-16 2017-11-13 Método de diagnóstico in vitro de la enfermedad de alzheimer basado en el nivel redox de la albúmina en el líquido cefalorraquídeo
HK18109862.6A HK1250395B (zh) 2016-11-16 2018-07-31 基於腦脊液中白蛋白氧化還原水平的阿爾茨海默病的體外診斷方法
US16/737,632 US20200141951A1 (en) 2016-11-16 2020-01-08 Vitro diagnostic method for alzheimer's disease based on the albumin redox level in the cerebrospinal fluid
US17/809,524 US20220326259A1 (en) 2016-11-16 2022-06-28 In vitro diagnostic method for alzheimer's disease based on the albumin redox level in the cerebrospinal fluid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201631468A ES2600386B8 (es) 2016-11-16 2016-11-16 Método de diagnóstico in vitro de la enfermedad de alzheimer basado en el nivel redox de la albúmina en el líquido cefalorraquídeo

Publications (3)

Publication Number Publication Date
ES2600386A1 ES2600386A1 (es) 2017-02-08
ES2600386B1 ES2600386B1 (es) 2017-07-10
ES2600386B8 true ES2600386B8 (es) 2017-08-04

Family

ID=57950791

Family Applications (2)

Application Number Title Priority Date Filing Date
ES201631468A Expired - Fee Related ES2600386B8 (es) 2016-11-16 2016-11-16 Método de diagnóstico in vitro de la enfermedad de alzheimer basado en el nivel redox de la albúmina en el líquido cefalorraquídeo
ES17200206T Active ES2706539T3 (es) 2016-11-16 2017-11-06 Método de diagnóstico in vitro de la Enfermedad de Alzheimer basado en el nivel redox de la albúmina en el líquido cefalorraquídeo

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES17200206T Active ES2706539T3 (es) 2016-11-16 2017-11-06 Método de diagnóstico in vitro de la Enfermedad de Alzheimer basado en el nivel redox de la albúmina en el líquido cefalorraquídeo

Country Status (23)

Country Link
US (3) US20180136236A1 (es)
EP (1) EP3324188B1 (es)
JP (1) JP6639457B2 (es)
KR (1) KR102189586B1 (es)
CN (1) CN108072762B (es)
AR (1) AR110065A1 (es)
AU (1) AU2017251853B2 (es)
BR (1) BR102017023388A2 (es)
CA (1) CA2984732C (es)
CL (1) CL2017002798A1 (es)
ES (2) ES2600386B8 (es)
HK (1) HK1250395B (es)
IL (1) IL255474B (es)
MX (1) MX2017014218A (es)
MY (1) MY179665A (es)
PL (1) PL3324188T3 (es)
PT (1) PT3324188T (es)
RU (1) RU2696485C2 (es)
SG (1) SG10201709117RA (es)
TR (1) TR201901544T4 (es)
TW (1) TWI699536B (es)
UY (1) UY37469A (es)
ZA (1) ZA201707484B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2600386B8 (es) * 2016-11-16 2017-08-04 Grifols Worldwide Operations Limited Método de diagnóstico in vitro de la enfermedad de alzheimer basado en el nivel redox de la albúmina en el líquido cefalorraquídeo

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5967456A (ja) * 1982-10-12 1984-04-17 Asahi Chem Ind Co Ltd クロマトグラフイ−によるアルブミンの分離方法
EP2369348A1 (en) * 2003-11-07 2011-09-28 Ciphergen Biosystems, Inc. Biomarkers for Alzheimer's disease
US9335331B2 (en) * 2005-04-11 2016-05-10 Cornell Research Foundation, Inc. Multiplexed biomarkers for monitoring the Alzheimer's disease state of a subject
JP5024044B2 (ja) * 2005-07-27 2012-09-12 味の素株式会社 試料溶液中のアルブミンの分析方法
CN102066938A (zh) * 2008-03-31 2011-05-18 学校法人久留米大学 伴随着肝病产生的水肿的判定方法
KR101352670B1 (ko) * 2010-06-15 2014-01-17 울산대학교 산학협력단 알츠하이머 전구단백질 분비 펩타이드의 축적물을 포함하는 뇌 노화 감별 진단 마커
EP2745117A2 (en) * 2011-08-18 2014-06-25 Medizinische Universität Graz Methods for diagnosing and treating medical conditions associated with oxidative stress
CA2926092A1 (en) * 2013-10-24 2015-04-30 Nanosomix, Inc. Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders
ES2600386B8 (es) * 2016-11-16 2017-08-04 Grifols Worldwide Operations Limited Método de diagnóstico in vitro de la enfermedad de alzheimer basado en el nivel redox de la albúmina en el líquido cefalorraquídeo

Also Published As

Publication number Publication date
MY179665A (en) 2020-11-11
ZA201707484B (en) 2019-11-27
JP2018081095A (ja) 2018-05-24
NZ736919A (en) 2020-06-26
AU2017251853B2 (en) 2021-03-25
EP3324188B1 (en) 2019-01-09
CN108072762A (zh) 2018-05-25
EP3324188A1 (en) 2018-05-23
IL255474A0 (en) 2017-12-31
TR201901544T4 (tr) 2019-02-21
PT3324188T (pt) 2019-01-29
AU2017251853A1 (en) 2018-05-31
TW201821801A (zh) 2018-06-16
CA2984732A1 (en) 2018-05-16
US20180136236A1 (en) 2018-05-17
ES2600386A1 (es) 2017-02-08
CL2017002798A1 (es) 2018-04-20
US20220326259A1 (en) 2022-10-13
RU2696485C2 (ru) 2019-08-02
BR102017023388A2 (pt) 2018-10-30
CA2984732C (en) 2021-10-26
RU2017137768A3 (es) 2019-07-17
KR20180055699A (ko) 2018-05-25
UY37469A (es) 2018-01-02
MX2017014218A (es) 2018-10-02
KR102189586B1 (ko) 2020-12-14
PL3324188T3 (pl) 2019-07-31
ES2706539T3 (es) 2019-03-29
AR110065A1 (es) 2019-02-20
ES2600386B1 (es) 2017-07-10
IL255474B (en) 2021-03-25
JP6639457B2 (ja) 2020-02-05
TWI699536B (zh) 2020-07-21
US20200141951A1 (en) 2020-05-07
CN108072762B (zh) 2022-03-08
HK1250395B (zh) 2019-09-27
SG10201709117RA (en) 2018-06-28
RU2017137768A (ru) 2019-04-30

Similar Documents

Publication Publication Date Title
EP4180815A3 (de) Immunologischer festphasen-test mit ortsaufgelöstem signal (sfida) zur quantifizierung von mindestens 2 proteinaggregaten
DK3954288T3 (da) Medicinsk anordning til påvisning af mindst én analyt i en kropsvæske
FR3052891B1 (fr) Procede d'estimation du facteur d'intensite des contraintes et procede de calcul de duree de vie associe
FR3016051B1 (fr) Procede de determination d'au moins un parametre geometrique d'une monture personnalisee de lunettes et procede de determination de la monture personnalisee associe
BR112015032507A2 (pt) método para derivar pontuação de fadiga, dispositivo de detecção de sonolência e elemento de programa de computador
DK3909506T3 (da) Medicinsk anordning til påvisning af mindst én analyt i en kropsvæske
CL2018001343A1 (es) Lactoferrina para uso en el diagnóstico o el pronóstico de la enfermedad de alzheimer o en el diagnóstico de la enfermedad de parkinson
MA45234A (fr) Anticorps anti-facteur xi de coagulation
WO2016132221A3 (en) Device, platform, and assay for assessing cells
EP3475707A4 (en) BLOOD TEST FOR THE EXCLUSION OF AMYLOID AND ALZHEIMER DISEASE
FR3041234B1 (fr) Appareil de determination d'un ou plusieurs parametres anatomiques faciaux d'un sujet
DK3500856T3 (da) Assay til bestemmelse af et proteins potentiale for at selvassociere ved hjælp af koncentrationsafhængig selvinteraktionsnanopartikelspektroskopi
ES2600386B8 (es) Método de diagnóstico in vitro de la enfermedad de alzheimer basado en el nivel redox de la albúmina en el líquido cefalorraquídeo
MX2018000528A (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
CL2019002099A1 (es) Resistencia a la enfermedad de hsmi en salmonidos.
CL2019002888A1 (es) Columna de separación de isótopos de alta longitud y método de ensamble
MX2019012439A (es) Herramienta de diagnostico para determinar el borramiento del proceso del pie del podocito.
MX2018000189A (es) Metodo para el diagnostico de la enfermedad de farber.
UA117256U (uk) Спосіб діагностики бронхіальної астми у дітей шляхом визначення вмісту протимікробних пептидів
DK3638109T3 (da) Fremgangsmåde til bestemmelse af koncentrationen af en analyt i fuldblod
Kozan et al. OP-175 Ratio of Aortic Flow Acceleration Time to Deceleration Time: A Novel Echocardiographic Parameter for Reduced LVEF?
Barsties et al. THE AVQI WITH EXTENDED REPRESENTATIVITY: EXTERNAL VALIDITY AND DIAGNOSTIC PRECISION WITH 1058 VOICE SAMPLES
TH174918B (th) "การทดสอบการแข็งตัวของเลือดแบบเอนกประสงค์ที่ใช้ไมโครฟลูอิดิกชิปเป็นหลัก"
IT201600131067A1 (it) Sistema per l’internet delle cose e visione artificiale applicato al settore dell’abbigliamento
UA97869U (ru) Способ определения выраженности нарушения среднего церебрального капиллярного давления

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2600386

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20170710

FD2A Announcement of lapse in spain

Effective date: 20220325